Clinical Trial Update: Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating carboplatin/paclitaxel with ABT-869 (linifanib) in advanced or metastatic non-small cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABT-869 (Linifanib) (linifanib)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED